Telix Reports Second Quarter 2022 Financial Results
MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2022. All figures are in AUD$ unless otherwise stated. All figures are provided on an unaudited basis. Financial Summary...
ImmVira’s intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities
SHENZHEN, China, July 21, 2022 /PRNewswire/ -- ImmVira's global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjects with late-stage pancreatic, colon, lung, endometrial, breast, head and neck, gastrointestinal cancers and other...
First report from the world’s most ambitious sequencing project
REYKJAVÍK, Iceland, July 20, 2022 /PRNewswire/ -- Scientists at deCODE genetics a subsidiary of Amgen together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature today. Bjarni V. Halldorsson leading author on the...
ABCAM PLC First Half Trading Update
CAMBRIDGE, England, July 20, 2022 /PRNewswire/ -- Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022. The Company will release its full results for the six-month period...
Recruitment complete for Clarity’s PROPELLER prostate cancer diagnostic trial
SYDNEY, July 20, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnostic trial evaluating its 64Cu-SAR-bisPSMA product candidate in patients with untreated, confirmed prostate cancer,...
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN12088 First-in-class new drug to quickly take on the pulmonary fibrosis market, predicted to reach $6.1 billion globally by 2030 SEOUL, South Korea, July 20, 2022 /PRNewswire/ -- As many Korean pharmaceutical manufacturers are currently attempting to...
VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model – Before or After Viral Exposure
MELBOURNE, Australia, July 20, 2022 /PRNewswire/ -- Starpharma's broad-spectrum VIRALEZE™ nasal spray has shown protection against infection with the highly transmissible SARS-CoV-2 Omicron variant in a stringent viral challenge model. VIRALEZE™ is a broad-spectrum barrier nasal spray, developed by Melbourne biotech company Starpharma, for application in the nasal cavity to help reduce exposure to virus. VIRALEZE™ is registered in more than...
BioWorld by Clarivate Explores the Concept of Extending Human Lifespan in New Report
Special report on aging investigates the latest science, key biological drivers and companies driving the development of potential "Fountain of Youth" candidate drugs LONDON, July 20, 2022 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, Extending the Human Lifespan,...
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
SAN FRANCISCO, ROCKVILLE, Md. and SUZHOU, China, July 20, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, and Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis...
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series FDA has determined that first vaccine lot has met all release specifications and is acceptable for use under Emergency Use Authorization Novavax expects to ship doses to the U.S. Government-designated distribution center...
